Literature DB >> 7910809

Neuroblastoma cell detection by reverse transcriptase-polymerase chain reaction (RT-PCR) for tyrosine hydroxylase mRNA.

S A Burchill1, F M Bradbury, B Smith, I J Lewis, P Selby.   

Abstract

The presence of tumour cells in peripheral blood of neuroblastoma patients is of considerable clinical importance. Nucleic acid amplification offers an opportunity to detect very small numbers of such cells, but in neuroblastoma a frequent specific abnormality in the tumour DNA suitable for this purpose has yet to be identified. To facilitate the detection of such cells we have developed RT-PCR using tyrosine hydroxylase (TH) as a tissue-specific target gene. TH mRNA was detected in 3 neuroblastoma cell lines and in all neuroblastoma tumours examined, but was undetectable in peripheral blood from children without neuroblastoma. The method was highly sensitive, detecting 1-10 neuroblastoma cells per 10(7) blood cells. Thirty blood samples from 24 patients were analysed and results were compared with known disease status. At diagnosis 4/7 patient blood specimens were positive; the four positive samples were from stage-4 patients. In blood samples from these patients 6-8 weeks after the initiation of treatment, TH mRNA was undetectable. Of 7 samples taken at the time of clinical relapse, 5 were positive; 4 of these were from patients with evidence of disseminating disease. Of 16 blood samples from disease-free patients, 14 were negative and 2 were positive. One positive patient in this group subsequently had a clinical relapse. These results show that this technique is of value for detecting neuroblastoma cells in peripheral blood. The significance of these cells at diagnosis, during treatment or on follow-up requires further evaluation.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7910809     DOI: 10.1002/ijc.2910570510

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  25 in total

1.  Tumor cell dynamics and metastasis in advanced neuroblastoma.

Authors:  Tatsuo Kuroda; Toshiro Honna; Nobuyuki Morikawa; Yoshihiro Kitano; Yasushi Fuchimoto; Kan Terawaki; Masaaki Kumagai; Yukiko Tsunematsu; Hidekazu Masaki; Kentaro Matsuoka; Morihiro Saeki
Journal:  Pediatr Surg Int       Date:  2005-11       Impact factor: 1.827

2.  Use of tumor-specific gene expression for the differential diagnosis of neuroblastoma from other pediatric small round-cell malignancies.

Authors:  J Gilbert; M Haber; S B Bordow; G M Marshall; M D Norris
Journal:  Am J Pathol       Date:  1999-07       Impact factor: 4.307

Review 3.  Cellular kinetics of neuroblastoma and the role of surgery.

Authors:  Tatsuo Kuroda
Journal:  Pediatr Surg Int       Date:  2011-07-19       Impact factor: 1.827

4.  Mobilization of tumour cells during biopsy in an infant with Ewing sarcoma.

Authors:  A Zoubek; H Kovar; M Kronberger; G Amann; R Windhager; B Gruber; H Gadner
Journal:  Eur J Pediatr       Date:  1996-05       Impact factor: 3.183

5.  Limited correlation between tumor markers and minimal residual disease detected by seven neuroblastoma-associated mRNAs in high-risk neuroblastoma patients.

Authors:  Suguru Uemura; Kyaw San Lin; Khin Kyae Mon Thwin; Naoko Nakatani; Toshiaki Ishida; Nobuyuki Yamamoto; Akihiro Tamura; Atsuro Saito; Takeshi Mori; Daiichiro Hasegawa; Yoshiyuki Kosaka; Nanako Nino; China Nagano; Satoru Takafuji; Kazumoto Iijima; Noriyuki Nishimura
Journal:  Mol Clin Oncol       Date:  2021-05-19

6.  Ganglioside GM2/GD2 synthetase mRNA is a marker for detection of infrequent neuroblastoma cells in bone marrow.

Authors:  D S Hoon; C T Kuo; S Wen; H Wang; L Metelitsa; C P Reynolds; R C Seeger
Journal:  Am J Pathol       Date:  2001-08       Impact factor: 4.307

7.  Bone marrow minimal residual disease was an early response marker and a consistent independent predictor of survival after anti-GD2 immunotherapy.

Authors:  Nai-Kong V Cheung; Irina Ostrovnaya; Deborah Kuk; Irene Y Cheung
Journal:  J Clin Oncol       Date:  2015-01-05       Impact factor: 44.544

8.  Comparison of the RNA-amplification based methods RT-PCR and NASBA for the detection of circulating tumour cells.

Authors:  S A Burchill; L Perebolte; C Johnston; B Top; P Selby
Journal:  Br J Cancer       Date:  2002-01-07       Impact factor: 7.640

9.  Expression of Wilms tumor gene in high risk neuroblastoma: complementary marker to tyrosine hydroxylase for detection of minimal residual disease.

Authors:  Morris Kletzel; Pauline M Chou; Marie Olszewski; Alfred W Rademaker; Sana Khan
Journal:  Transl Pediatr       Date:  2015-07

10.  Consensus criteria for sensitive detection of minimal neuroblastoma cells in bone marrow, blood and stem cell preparations by immunocytology and QRT-PCR: recommendations by the International Neuroblastoma Risk Group Task Force.

Authors:  K Beiske; S A Burchill; I Y Cheung; E Hiyama; R C Seeger; S L Cohn; A D J Pearson; K K Matthay
Journal:  Br J Cancer       Date:  2009-04-28       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.